The story of late actress Hayden Panettiere shows why postpartum depression cannot be dismissed as a difficult adjustment to motherhood. Panettiere’s tragic story brought renewed attention to the condition which can be difficult to recognise, even when a woman is surrounded by wealth, professional success and people who care about her.
The Heroes and Nashville actress spoke publicly about developing severe postpartum depression after the birth of her daughter, Kaya, in 2014. In her 2026 memoir, This Is Me: A Reckoning, she described a traumatic childbirth involving a C-section, extensive surgery and seven blood transfusions.
She subsequently experienced anxiety, emotional distress and what she later recognised as postpartum depression. Her account describes turning to alcohol and prescription medication in an attempt to cope with what she was experiencing.
Panettiere died on 16 August this year (2026), aged 36.
Her story demonstrates how a postpartum mental-health disorder can become part of a much longer and more complicated clinical journey when it is severe, inadequately recognised or accompanied by substance use.
Postpartum depression is sometimes still treated as an inevitable part of becoming a mother. However, it is not.
According to the World Health Organisation, more than 10 percent of pregnant women and women who have recently given birth experience depression globally. WHO estimates that the proportion is considerably higher in developing countries, where around 19.8 percent of women experience a mental disorder after childbirth.
In other words, postpartum depression is common enough that it should be regarded as a routine part of maternal healthcare rather than an unusual psychiatric event.
There is also an important lesson in Panettiere’s account about what postpartum depression can look like.
It does not necessarily mean that a mother dislikes her baby or does not want to be a mother. A woman can love her child intensely while simultaneously experiencing depression, anxiety, emotional numbness or a frightening sense of disconnection.
Symptoms can include persistent sadness or emptiness, loss of interest or pleasure, severe fatigue, sleep disturbance, changes in appetite, anxiety, irritability, feelings of worthlessness or guilt, difficulty concentrating and withdrawing from other people. Some women experience frightening thoughts about harming themselves or their baby.
The difference between the so-called ‘baby blues’ and postpartum depression is particularly important. The baby blues commonly begin within a few days of delivery and generally resolve within one to two weeks. Postpartum depression is more intense and persistent and can interfere with daily functioning. It can begin during pregnancy or at any point during the first year after childbirth.
Panettiere’s experience also illustrates why clinicians increasingly view postpartum depression through a biological, as well as psychological, lens.
Childbirth produces dramatic physiological changes. Levels of hormones, including oestrogen and progesterone fall sharply after delivery, while sleep deprivation, physical recovery, breastfeeding difficulties, relationship pressures and stressful life events can add further strain.
A history of depression or other mental-health problems can increase vulnerability, but postpartum depression can also occur in women without a previous psychiatric diagnosis.
A difficult birth does not automatically cause postpartum depression, and not every woman who experiences a complicated delivery will develop it. However, physical complications, severe stress and inadequate recovery can contribute to psychological vulnerability.
The most intriguing question is whether the future of postpartum depression diagnosis could extend beyond questionnaires and clinical interviews.
At present, clinicians rely heavily on clinical assessment and validated screening tools such as the Edinburgh Postnatal Depression Scale and PHQ-9. The American College of Obstetricians and Gynecologists recommends screening for depression and anxiety at the initial prenatal visit, later in pregnancy and during postpartum care, with systems in place for assessment, treatment and follow-up.
However, researchers are increasingly investigating whether there are measurable changes in the brain that could eventually help identify women at risk.
A 2026 review by Linfeng Yang and colleagues, published in Behavioural Brain Research under the title ‘Neuroimaging biomarkers in postpartum depression: A comprehensive review of structural, functional, and metabolic alterations’, found evidence of structural, functional and metabolic brain differences associated with postpartum depression.
The review reported that structural MRI studies have identified changes in areas including the dorsolateral prefrontal cortex and anterior insula, while functional MRI research has found altered activity and connectivity involving regions such as the amygdala, hippocampus and prefrontal cortex.
Metabolic imaging studies using techniques including magnetic resonance spectroscopy and PET have also identified potential abnormalities involving neurotransmitters such as serotonin, glutamate and GABA, providing further insight into the neurobiological mechanisms that may contribute to postpartum depression.
This does not mean that a brain scan can currently diagnose postpartum depression. The research is still largely exploratory. Studies differ in their populations, imaging techniques and definitions of postpartum depression, and researchers themselves are calling for larger samples, multimodal imaging and longer-term studies.
The eventual ambition is to move from simply observing that postpartum depression is associated with brain changes to determining whether imaging could identify biological signatures capable of predicting risk, treatment response or relapse.This could become particularly important because postpartum depression does not respond identically to treatment in every woman.
Medication can also be effective. A systematic review of 11 randomised trials involving 1 016 women found that SSRIs produced a response rate of approximately 55 percent, compared with 43 percent for placebo, while remission occurred in approximately 42 percent versus 27 percent, although the researchers stressed that the evidence was not definitive and varied between studies.
Treatment has also entered a new era. In 2023, the US Food and Drug Administration approved Zuranolone, the first oral medication specifically indicated for postpartum depression. It is a neuroactive steroid taken once daily for 14 days. In the two clinical trials supporting approval, involving 345 patients, depressive symptoms improved significantly more with Zuranolone than with placebo, with the treatment effect maintained four weeks after the treatment course ended.
Panettiere is far from the only public figure to reveal how profoundly postpartum depression can affect a woman. Brooke Shields wrote about her experience after the birth of her daughter, describing a severe depression which ultimately improved with treatment. Singer Adele has also spoken about experiencing severe postnatal depression after the birth of her son.
Their stories share a striking message. This is that outward circumstances are not a reliable indicator of inner wellbeing. A woman can be successful, financially secure, loved, excited about her baby and apparently functioning normally, yet still be seriously depressed.
Women experiencing these symptoms should consider a message from the American Pregnancy Association reads: ”Bringing a baby into the world is lifechanging. Alongside joy and awe, many parents experience emotional shifts that can feel surprising or intense. Hormones change rapidly after birth. Sleep becomes fragmented. Identity evolves. Responsibility deepens. If you feel overwhelmed, tearful, anxious, or different than expected, you are not alone.”
(Photo: Depositphotos.com).